@article{5fe98f49392a427284dd84455f491f8c,
title = "EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours",
author = "\{on behalf of the EANO Executive Board and ESMO Guidelines Committee\} and \{Le Rhun\}, E. and M. Weller and D. Brandsma and \{Van den Bent\}, M. and \{de Azambuja\}, E. and R. Henriksson and T. Boulanger and S. Peters and C. Watts and W. Wick and P. Wesseling and R. Rud{\`a} and M. Preusser",
note = "Funding Information: ELR has received research support from Mundipharma and Amgen. MW has received research grants from Acceleron, Actelion, Bayer, Isarna, MSD, Merck EMD, Novocure, Piqur and Roche and honoraria for lectures or advisory board participation or consulting from Bristol-Myers Squibb, Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck EMD, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva and Tocagen. MVdB has received research support from BBB therapeutics. EdA has received advisory board from Roche; travels grant from Roche and GlaxoSmithKline; research grant from Roche. WW has received research support from Pfizer, Apogenix, MSD and Roche and has reported being a member of the speaker{\textquoteright}s bureau of Brystol-Myers Squibb and MSD. MP has received research support from B{\"o}hringer-Ingelheim, GlaxoSmithKline, Merck Sharp \& Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche and AstraZeneca. DB, RH, TB, SP, CW, WW, PW and RR have declared no potential conflicts of interest.",
year = "2017",
doi = "10.1093/annonc/mdx221",
language = "English",
volume = "28",
pages = "iv84--iv99",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd.",
}